JP2023546452A - 眼障害を処置するための化合物および方法 - Google Patents
眼障害を処置するための化合物および方法 Download PDFInfo
- Publication number
- JP2023546452A JP2023546452A JP2023524274A JP2023524274A JP2023546452A JP 2023546452 A JP2023546452 A JP 2023546452A JP 2023524274 A JP2023524274 A JP 2023524274A JP 2023524274 A JP2023524274 A JP 2023524274A JP 2023546452 A JP2023546452 A JP 2023546452A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- radical
- alkyl
- pharmaceutically acceptable
- heteroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063094808P | 2020-10-21 | 2020-10-21 | |
| US63/094,808 | 2020-10-21 | ||
| PCT/IB2021/000708 WO2022084739A1 (en) | 2020-10-21 | 2021-10-20 | Compounds and methods for the treatment of ocular disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546452A true JP2023546452A (ja) | 2023-11-02 |
| JP2023546452A5 JP2023546452A5 (https=) | 2024-10-29 |
Family
ID=81290138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023524274A Pending JP2023546452A (ja) | 2020-10-21 | 2021-10-20 | 眼障害を処置するための化合物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230399317A1 (https=) |
| EP (1) | EP4232034A4 (https=) |
| JP (1) | JP2023546452A (https=) |
| KR (1) | KR20230110516A (https=) |
| CN (1) | CN116635032A (https=) |
| AU (1) | AU2021365530A1 (https=) |
| CA (1) | CA3196146A1 (https=) |
| IL (1) | IL302174A (https=) |
| MX (1) | MX2023004538A (https=) |
| WO (1) | WO2022084739A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024100454A2 (en) * | 2022-11-11 | 2024-05-16 | Azura Ophthalmics Ltd. | Composition and methods for improving signs and symptoms of ocular disorders |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011500683A (ja) * | 2007-10-19 | 2011-01-06 | サーコード コーポレーション | 糖尿病性網膜症の治療のための組成物及び方法 |
| JP2018533622A (ja) * | 2015-09-28 | 2018-11-15 | アズーラ オフサルミックス エルティーディー． | マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤 |
| WO2019053607A1 (en) * | 2017-09-18 | 2019-03-21 | Glenmark Pharmaceuticals Limited | PROCESS FOR PREPARING LIFITEGRAST |
| WO2019096996A1 (en) * | 2017-11-17 | 2019-05-23 | Medichem, S.A. | A process to obtain a tetrahydroisoquinoline derivative |
| JP2020515533A (ja) * | 2017-03-29 | 2020-05-28 | アズーラ オフサルミックス エルティーディー． | マイボーム腺脂質分泌を増加させるための薬剤 |
| JP2020523406A (ja) * | 2017-05-19 | 2020-08-06 | オクジェン アイエヌシー． | 眼科用組成物および使用方法 |
| JP7700045B2 (ja) * | 2019-04-18 | 2025-06-30 | アズーラ オフサルミックス エルティーディー． | 眼障害を処置するための化合物および方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090257957A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders |
| BR112015014367B1 (pt) * | 2012-12-19 | 2022-11-22 | Novartis Ag | Composição inibidora de lfa-1, método para estabilizar a dita composição e uso da mesma para tratar uma doença ocular |
| US9463201B2 (en) * | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| JP2019513775A (ja) * | 2016-04-19 | 2019-05-30 | アズーラ オフサルミックス エルティーディー． | 角化症の処置のための組成物 |
| US20180333357A1 (en) * | 2017-05-19 | 2018-11-22 | Ocugen, Inc. | Nanoemulsions with anti-inflammatory activity |
| WO2020212755A1 (en) * | 2019-04-18 | 2020-10-22 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
-
2021
- 2021-10-20 EP EP21882227.8A patent/EP4232034A4/en active Pending
- 2021-10-20 KR KR1020237016473A patent/KR20230110516A/ko active Pending
- 2021-10-20 IL IL302174A patent/IL302174A/en unknown
- 2021-10-20 WO PCT/IB2021/000708 patent/WO2022084739A1/en not_active Ceased
- 2021-10-20 JP JP2023524274A patent/JP2023546452A/ja active Pending
- 2021-10-20 AU AU2021365530A patent/AU2021365530A1/en not_active Abandoned
- 2021-10-20 MX MX2023004538A patent/MX2023004538A/es unknown
- 2021-10-20 CA CA3196146A patent/CA3196146A1/en active Pending
- 2021-10-20 US US18/033,055 patent/US20230399317A1/en active Pending
- 2021-10-20 CN CN202180086872.2A patent/CN116635032A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011500683A (ja) * | 2007-10-19 | 2011-01-06 | サーコード コーポレーション | 糖尿病性網膜症の治療のための組成物及び方法 |
| JP2018533622A (ja) * | 2015-09-28 | 2018-11-15 | アズーラ オフサルミックス エルティーディー． | マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤 |
| JP2020515533A (ja) * | 2017-03-29 | 2020-05-28 | アズーラ オフサルミックス エルティーディー． | マイボーム腺脂質分泌を増加させるための薬剤 |
| JP2020523406A (ja) * | 2017-05-19 | 2020-08-06 | オクジェン アイエヌシー． | 眼科用組成物および使用方法 |
| WO2019053607A1 (en) * | 2017-09-18 | 2019-03-21 | Glenmark Pharmaceuticals Limited | PROCESS FOR PREPARING LIFITEGRAST |
| WO2019096996A1 (en) * | 2017-11-17 | 2019-05-23 | Medichem, S.A. | A process to obtain a tetrahydroisoquinoline derivative |
| JP7700045B2 (ja) * | 2019-04-18 | 2025-06-30 | アズーラ オフサルミックス エルティーディー． | 眼障害を処置するための化合物および方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023004538A (es) | 2023-06-19 |
| KR20230110516A (ko) | 2023-07-24 |
| CN116635032A (zh) | 2023-08-22 |
| AU2021365530A1 (en) | 2023-06-15 |
| EP4232034A4 (en) | 2024-12-04 |
| CA3196146A1 (en) | 2022-04-28 |
| EP4232034A1 (en) | 2023-08-30 |
| AU2021365530A9 (en) | 2024-02-08 |
| WO2022084739A1 (en) | 2022-04-28 |
| IL302174A (en) | 2023-06-01 |
| US20230399317A1 (en) | 2023-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11643429B2 (en) | Compounds and methods for the treatment of ocular disorders | |
| JP7700045B2 (ja) | 眼障害を処置するための化合物および方法 | |
| JP2023546453A (ja) | 眼障害を処置するための化合物および方法 | |
| JP2023546915A (ja) | 眼障害を処置するための化合物および方法 | |
| WO2020212755A1 (en) | Compounds and methods for the treatment of ocular disorders | |
| JP2023546452A (ja) | 眼障害を処置するための化合物および方法 | |
| US20250042931A1 (en) | Compounds and methods for the treatment of ocular disorders | |
| CN116940570A (zh) | 用于治疗眼部病症的化合物和方法 | |
| HK40100091A (zh) | 用於治疗眼部病症的化合物和方法 | |
| HK40100700A (zh) | 用於治疗眼部病症的化合物和方法 | |
| HK40068671A (en) | Compounds and methods for the treatment of ocular disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230703 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241018 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241018 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250814 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250825 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260126 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260406 |